Trial of penicillamine in advanced primary billary cirrhosis

E. R. Dickson, T. R. Fleming, R. H. Wiesner, W. P. Baldus, J. Ludwig, J. T. McCall

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

A total of 227 patients with histologically advanced primary biliary cirrhosis entered a double-blind, randomized, controlled trial to determine whether penicillamine (1 g per day) was therapeutically effective; 111 patients received the drug, and 116 received placebo. The two groups were highly comparable at entry with regard to clinical, biochemical and histologic features. Penicillamine therapy did not result in an overall improvement in survival as compared with placebo. Clinical symptoms and serial hepatic laboratory values reflected the progressive nature of the disease and were similar in both groups. There were no substantial differences between treatment groups in the morphologic features of sequential biopsy specimens. The development of major side effects led to permanent discontinuation of penicillamine in 22% of the patients taking the drug. We conclude that penicillamine is not useful for patients with histologically advanced primary biliary cirrhosis. The trial is being continued in patients with early histologic disease whose better prognosis necessitates longer follow-up.

Original languageEnglish (US)
Pages (from-to)1011-1015
Number of pages5
JournalNew England Journal of Medicine
Volume312
Issue number16
StatePublished - 1985

Fingerprint

Penicillamine
Fibrosis
Biliary Liver Cirrhosis
Placebos
Pharmaceutical Preparations
Randomized Controlled Trials
Biopsy
Survival
Liver
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dickson, E. R., Fleming, T. R., Wiesner, R. H., Baldus, W. P., Ludwig, J., & McCall, J. T. (1985). Trial of penicillamine in advanced primary billary cirrhosis. New England Journal of Medicine, 312(16), 1011-1015.

Trial of penicillamine in advanced primary billary cirrhosis. / Dickson, E. R.; Fleming, T. R.; Wiesner, R. H.; Baldus, W. P.; Ludwig, J.; McCall, J. T.

In: New England Journal of Medicine, Vol. 312, No. 16, 1985, p. 1011-1015.

Research output: Contribution to journalArticle

Dickson, ER, Fleming, TR, Wiesner, RH, Baldus, WP, Ludwig, J & McCall, JT 1985, 'Trial of penicillamine in advanced primary billary cirrhosis', New England Journal of Medicine, vol. 312, no. 16, pp. 1011-1015.
Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Ludwig J, McCall JT. Trial of penicillamine in advanced primary billary cirrhosis. New England Journal of Medicine. 1985;312(16):1011-1015.
Dickson, E. R. ; Fleming, T. R. ; Wiesner, R. H. ; Baldus, W. P. ; Ludwig, J. ; McCall, J. T. / Trial of penicillamine in advanced primary billary cirrhosis. In: New England Journal of Medicine. 1985 ; Vol. 312, No. 16. pp. 1011-1015.
@article{b87afe5bd5354c109af2075301d2bc69,
title = "Trial of penicillamine in advanced primary billary cirrhosis",
abstract = "A total of 227 patients with histologically advanced primary biliary cirrhosis entered a double-blind, randomized, controlled trial to determine whether penicillamine (1 g per day) was therapeutically effective; 111 patients received the drug, and 116 received placebo. The two groups were highly comparable at entry with regard to clinical, biochemical and histologic features. Penicillamine therapy did not result in an overall improvement in survival as compared with placebo. Clinical symptoms and serial hepatic laboratory values reflected the progressive nature of the disease and were similar in both groups. There were no substantial differences between treatment groups in the morphologic features of sequential biopsy specimens. The development of major side effects led to permanent discontinuation of penicillamine in 22{\%} of the patients taking the drug. We conclude that penicillamine is not useful for patients with histologically advanced primary biliary cirrhosis. The trial is being continued in patients with early histologic disease whose better prognosis necessitates longer follow-up.",
author = "Dickson, {E. R.} and Fleming, {T. R.} and Wiesner, {R. H.} and Baldus, {W. P.} and J. Ludwig and McCall, {J. T.}",
year = "1985",
language = "English (US)",
volume = "312",
pages = "1011--1015",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - Trial of penicillamine in advanced primary billary cirrhosis

AU - Dickson, E. R.

AU - Fleming, T. R.

AU - Wiesner, R. H.

AU - Baldus, W. P.

AU - Ludwig, J.

AU - McCall, J. T.

PY - 1985

Y1 - 1985

N2 - A total of 227 patients with histologically advanced primary biliary cirrhosis entered a double-blind, randomized, controlled trial to determine whether penicillamine (1 g per day) was therapeutically effective; 111 patients received the drug, and 116 received placebo. The two groups were highly comparable at entry with regard to clinical, biochemical and histologic features. Penicillamine therapy did not result in an overall improvement in survival as compared with placebo. Clinical symptoms and serial hepatic laboratory values reflected the progressive nature of the disease and were similar in both groups. There were no substantial differences between treatment groups in the morphologic features of sequential biopsy specimens. The development of major side effects led to permanent discontinuation of penicillamine in 22% of the patients taking the drug. We conclude that penicillamine is not useful for patients with histologically advanced primary biliary cirrhosis. The trial is being continued in patients with early histologic disease whose better prognosis necessitates longer follow-up.

AB - A total of 227 patients with histologically advanced primary biliary cirrhosis entered a double-blind, randomized, controlled trial to determine whether penicillamine (1 g per day) was therapeutically effective; 111 patients received the drug, and 116 received placebo. The two groups were highly comparable at entry with regard to clinical, biochemical and histologic features. Penicillamine therapy did not result in an overall improvement in survival as compared with placebo. Clinical symptoms and serial hepatic laboratory values reflected the progressive nature of the disease and were similar in both groups. There were no substantial differences between treatment groups in the morphologic features of sequential biopsy specimens. The development of major side effects led to permanent discontinuation of penicillamine in 22% of the patients taking the drug. We conclude that penicillamine is not useful for patients with histologically advanced primary biliary cirrhosis. The trial is being continued in patients with early histologic disease whose better prognosis necessitates longer follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0021946190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021946190&partnerID=8YFLogxK

M3 - Article

VL - 312

SP - 1011

EP - 1015

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 16

ER -